Clinical Trial Update: Six Months Efficacy and Safety of Aliskiren Therapy on Top of Standard Therapy, on Morbidity and Mortality in Patients With Acute Decompensated Heart Failure [Phase 3]

View source ↗

Summary

A Phase 3 trial tested six months of aliskiren added to standard therapy in patients with acute decompensated heart failure and reported on morbidity and mortal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Decompensated Heart Failure
• Heart Failure

Drugs mentioned

• Aliskiren (Aliskiren)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acute Decompensated Heart Failure, Congestive Heart Failure | Phase 3 | Status: COMPLETED | Results posted: 2013-10-10